is...retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To me none of that matters if he brings our dog to the attention of the "right" people.
Question
Does anyone know if there has been study in Italy of those taking our pill for bowel problem never got the corona virus?
I know this is a badly worded question but you get my drift.
Best one yet
There is more than a 50% chance that Kudlow knows abut B
Gov
Makes me wonder how we ever built the A bomb when we needed it. How many will needlessly die before the end of the year?
Word to the right person would cut this time to zero.
Now if we hear from wild - the gang is all here.
Could it be Larry kudlow?
I saw it too. Gov
They gave b to a participant after a dose of B to test it as vaccine
Weren't we supposed to get top line data this week?
Wild it is now or never
for pete"s sake somebody better say something. what's the matter with Leo?
Wonderful
Keep it up please!!
Very nice to see you participating again.
I thought that was very good news this morning. Especially for those that have this problem. I only wish things would move along faster.
It is at a location not likely to draw many observers.
Thanks a lot for answering me. Is there a way to find out what the Italian company makes per year on its
drug that B UP will be replacing?
thanks to both of you. I thought I read somewhere that B-UP sales would be one billion yearly.
What is 6% of 1 billion?
https://www.alfasigma.com/CMSContent/Alfasigma2017/financialHighlights2.jpg
Can you tell from this what the sales are for RFR and RFN? Shouldn't 6% of that give us some idea what B-UP is worth?
Some of you computer savvy types ought to be able to find out what approximate 2019 revenues are for the product LE signed up for. Something similar
Something like this
Exclusive license agreement for LPLDL®
Twitter
Facebook
LinkedIn
GooglePlus
Pinterest
JUNE 21, 2018Source: RNS
RNS Number : 0523S
OptiBiotix Health PLC
21 June 2018
21 June 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exclusive license agreement for LPLDL®
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into license agreement with ALFASIGMA S.p.A. ("ALFASIGMA") to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy.
The agreement is a 10 year exclusive license agreement with an upfront payment and royalties with five figure guaranteed annual minimum payments. Under the terms of the agreement, ALFASIGMA will obtain the license to promote food supplements containing LPLDL® throughout Italy for cardiovascular health, with the aim of maximising the financial return for both parties.
ALFASIGMA, is an integrated multinational pharmaceutical company with 2017 revenue in excess of €1 billion and 2800 employees globally. Outside of its core Italian market, ALFASIGMA has 16 subsidiaries in Europe, Asia, North & Central America and Africa, and has authorised distributors in more than 70 countries. More than 44% of ALFASIGMA turnover comes from internally developed proprietary products. One of these, Normix/Xifaxan, has reached a worldwide turnover in excess of €1.3 billion through ALFASIGMA partners.
This agreement follows on from the launch of LPLDL® in the USA and is a strategic step to access high value high growth markets around the world. It extends the commercialisation of LPLDL® into Italy, the largest probiotic supplement market in Europe, and the second largest market in the world. Italy is an estimated >$500 million probiotic supplements market with a 25% per annum growth forecast to 2021*.
*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).
Per Rehne, Commercial Director of OptiBiotix, commented: "We are excited to announce this 10 year exclusive agreement with ALFASIGMA which expands sales of LPLDL® into Italy, the largest and fastest growing probiotic market in Europe. ALFASIGMA are one of the largest pharmaceutical companies in Italy with a strong track record in food supplements and pharmaceuticals for cardiovascular health. This agreement provides upfront and guaranteed minimum future payments with LPLDL® offered in multiple product solutions to consumers in Italy. This agreement is another deal from a very strong pipeline with industry partners of increasing size and revenue potential targeted at the largest and fastest growing markets around the world."
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
AGRBUGDLISDBGIG
Twitter
Facebook
LinkedIn
GooglePlus
Pinterest
Explore our tools
Alerts
Data archive
Portfolio
World markets
Equities screener
Funds overview
Support
View Site Tips
Help Centre
About Us
Accessibility
myFT Tour
Careers
Legal & Privacy
Terms & Conditions
Privacy
Cookies
Copyright
Slavery Statement & Policies
Services
FT Live
Share News Tips Securely
Individual Subscriptions
Group Subscriptions
Republishing
Contracts & Tenders
Executive Job Search
Advertise with the FT
Follow the FT on Twitter
FT Transact
Secondary Schools
Tools
Portfolio
Today's Newspaper (ePaper)
Alerts Hub
MBA Rankings
Enterprise Tools
News feed
Newsletters
Currency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
I hate to press you on this BUT is there a way to find out how much income Apasigma gets for the drug they have now for this malady? Also I am not sure I remember long ago things anymore but it seems to me LE was taking Pruisol to europe because they had a quick way to do the testing. He even named a patent lawyer or some kind of lawyer to hurry the process along but maybe that was because HIV infected persons had already passed some of the tests so a 2 year play may not be in the cards.
When will B-UP be ready to be used worldwide (with the exception of USA).
I understand that Aspasigma is paying for this preparation?
Worldwide what do you suppose the profit will be on this?
What will IPIX cut of 6% come to? 46 million yearly sound right?
what is the current income Apasigmo receives now for the current drug they are using for the B-UP problem? When will the IPIX treatment be ready to be used instead?
Didn't someone post what the expected revenue would be for B-UP from that Italian firm for a year? I thought IPIX would get 45 + per year.
Cellceutix Provides Update on Developing p53 Drug Candidate ...
www.ipharminc.com/.../cellceutix-provides-update-on-developing-p53-drug-candidat...
Mar 3, 2017 - Based on positive results from Cellceutix's Phase 1 trial of Kevetrin in solid ... In related news: Last week, Cellceutix research partners in Italy shared results ... Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and ...
Innovation Pharmaceuticals Provides Corporate Update Highlighting ...
www.ipharminc.com/.../innovation-pharmaceuticals-provides-corporate-update-highli...
2 days ago - ... with Alfasigma—an Italy-based multinational pharmaceutical company ... These results further support Kevetrin's treatment potential in AML, ...
Cellceutix Provides Update on Developing p53 ... - Globe Newswire
https://globenewswire.com/.../Cellceutix-Provides-Update-on-Developing-p53-Drug-C...
Mar 3, 2017 - Based on positive results from Cellceutix's Phase 1 trial of Kevetrin in solid ... In related news: Last week, Cellceutix research partners in Italy shared results ... Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and ...
Kevetrin | Innovation Pharma (Formerly known as Cellceutix ...
https://deals.bio/search/showOpportunityDetails?asset_id=2760
Jan 21, 2018 - The University of Bologna in Italy plans on testing Kevetrin for efficacy against Acute Myelogenous Leukemia (AML). The planned Phase 1B is ...
Italy Anti-Money Laundering – Getting The Deal Through – GTDT
https://gettingthedealthrough.com/area/50/jurisdiction/.../anti-money-laundering-italy/
As far as criminal provisions are concerned, money laundering is a criminal offence provided for in article 648-bis of the Italian Criminal Code (ICC), which ...
Missing: kevetrin ?| Must include: kevetrin
The New Italian Measures on AML - Lexology
https://www.lexology.com/library/detail.aspx?g=d309d621-8906-4c27-9169...
Jul 5, 2017 - Italy recently implemented the IV AML Directive via legislative decree 25 May 2017 n. 90 (“the Decree”). The Decree has entered into force on ...
Missing: kevetrin ?| Must include: kevetrin
Cellceutix Provides Update on Developing p53 Drug Candidate ...
https://www.worldpharmatoday.com/.../cellceutix-provides-update-on-developing-p5...
Based on positive results from Cellceutix's Phase 1 trial of Kevetrin in solid tumors ... In related news: Last week, Cellceutix research partners in Italy shared ... work evaluating Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and ...
A Multi-Center, Open-Label, Phase I/II Study Of Kevetrin With ...
https://adisinsight.springer.com/trials/700222905
A Multi-Center, Open-Label, Phase I/II Study Of Kevetrin With Cytarabine In Patients ... The primary objective of this trial is to evaluate the rate of complete remission of AML in patients receiving Kevetrin ... University of Bologna, Bologna, Italy ...
FORM 10-K - SEC.gov
https://www.sec.gov/Archives/edgar/data/1355250/.../annual2013_10k.htm
Our flagship compound, Kevetrin, is a drug that has shown promising laboratory data as a ..... The University of Bologna in Italy (the “University”) and The Italian ... Group) plan on testing Kevetrin against Acute Myelogenous Leukemia (AML).
KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ...
https://library.ehaweb.org/.../roberta.napolitano.kevetrin.preclinical.study.of.a.new.co...
Acute Myeloid Leukemia (AML) is a heterogeneous disorder defined by clonal expansion of immature myeloid cells that infiltrate bone marrow and other tissues .
Ad
R/R AML Treatment Option - Information for Physicians?
AdPrescription treatment website?
View Efficacy & Response Rate Data For A Targeted Treatment For R/R AML. Mechanism of Action. Physician Information. Efficacy Information. 250mg Tablets. Request a Visit. Full Prescribing Info. Dosing Schedule. Reimbursement Info. Types: Patient Resources, Access & Reimbursement.
Dosing InformationEfficacy & Clinical InfoClinical ResourcesInfo & Boxed Warning
Page Navigation
1
2
3
4
5
6
7
8
9
10
Next
That AML trial was set up 7 or 8 years ago with an Italian hospital. Children were suppose to be the patients. It fell through because the Italian hospital lacked funds and so did IPIX.
That ells you what runs these things.
Dear Mr. Slowpoke (AKA LE)
It iiS time to put the pedal to the metal. 88 just around the corner
Guess Who
It was a joke!!!!
I agree with you. The agony is over.
Yeah - just trying to give LE an idea. Would serve all the certain somebodies right?
Someone said to me that LE is going to make public the initial payment tomorrow at 3:58 pm
I hope someone can translate the statement in Italian about this deal. Lilkahuna must know someone who is bilingual or the canal guy.
The posts on this board since the latest news remind me of traveling in a car with kids in the back seat before computers. I consider myself a part of this problem.
I say let's hear from KarenCa. It seems to me too coincidental she returned just in time for this, I think she knows everything.
I personally am pleased with the deal. All pluses and validates all the things leo said would happen. Too bad for Pfizer. They missed a great opportunity. All the big pharma are afraid of Trump right now and they should be imo.
flop sweat
congrats Wild